After being the only one to finish 2016 in the red, the healthcare sector made a comeback in 2017 and finished the year up 21.7%, barely lagging the S&P 500’s (SPX) 21.83% increase. It’s still early in the year, but so far the sector’s performance has been in line with the SPX.
As is often the case, that could change once Q1 earnings season gets underway next month. For the quarter, the S&P 500 healthcare sector is expected to report 9.5% earnings growth and 6.5% revenue growth, according to FactSet. The projected earnings growth for the sector has increased over the past several months and back on Dec. 31, it was only 4.5%.
There are a few companies that have yet to confirm their earnings release dates. Here are some of the third-party consensus analyst estimates for ones that have announced their reporting dates:
- Johnson & Johnson (JNJ) reports before market open on Apr. 17. JNJ is expected by Wall Street consensus to report adjusted earnings per share (EPS) of $2.01 on revenue of $19.38 billion, compared to $1.83 on revenue of $18 billion in Q1 2017.
- Eli Lilly (LLY) reports before market open on Apr. 24. Based on Wall Street consensus estimates, LLY is expected to report adjusted EPS of $1.13 on revenue of $5.47 billion, compared to $0.98 on revenue of $5.23 billion in Q1 2017.
- Merck (MRK) reports before market open on May 1. MRK is expected to report adjusted EPS of $0.98 on revenue of $9.94 billion, compared to $0.88 on revenue of $9.43 billion in Q1 2017
- Cigna (CI) reports before market open on May 3. CI is expected to report adjusted EPS of $3.38 on revenue of $11.02 billion, compared to $2.77 on revenue of $10.34 billion in Q1 2017.
These are third-party consensus analyst estimates for some of the major healthcare companies that have yet to confirm earnings release dates (most are expected to report in mid-to-late April and early May):
- Abbvie (ABBV) is expected to report adjusted EPS of $1.78 on revenue of $7.56 billion, compared to $1.28 on revenue of $6.54 billion in Q1 2017.
- Celgene (CELG) is expected to report adjusted EPS of $1.99 on revenue of $3.49 billion, compared to $1.68 on revenue of $3.04 billion in Q1 2017.
- CVS Health (CVS) is expected to report adjusted EPS of $1.40 on revenue of $45.82 billion, compared to $1.17 on revenue of $44.51 billion in Q1 2017.
- Gilead (GILD) is expected to report adjusted EPS of $1.61 on revenue of $5.39 billion, compared to $2.23 on revenue of $6.51 billion in Q1 2017.
- Pfizer (PFE) is expected to report adjusted EPS of $0.73 on revenue of $12.9 billion, compared to $0.69 on revenue of $12.78 billion in Q1 2017.
- United Health Group (UNH) is expected to report adjusted EPS of $2.92 on revenue of $54.85 billion, compared to $2.37 on revenue of $48.72 billion in Q1 2017.
Looking back at Q4 2017, 84% of the companies in the S&P 500 healthcare sector reported earnings above estimates, 5% were in line with estimates, and 11% came in below, according to FactSet.
Volatility in Insurance and Providers
One of the big things that happened early on in the year was Amazon (AMZN), Berkshire Hathaway (BRK.B), and JPMorgan Chase’s (JPM) announcement on Jan. 30 that the three would be teaming up to address U.S. employee healthcare. At the time, JPM CEO Jamie Dimon said “our goal is to create solutions that benefit our U.S. employees, their families, and, potentially, all Americans.”
Those aren’t exactly three companies you want to hear are entering your industry, especially when there are few details about the new partnership that the three said will be “free from profit-making incentives and constraints.” Following the announcement, shares of insurance providers (see below) were sharply lower, and other healthcare companies including CVS Health (CVS), Walgreens Boots Alliance (WBA) and drug wholesaler AmerisourceBergen (ABC), among others, also took a hit. One thing that remains to be seen is whether or not all of this will end up spilling over into other parts of the sector.
On top of the volatility driven by competitive pressures, drug pricing and other regulatory concerns have continued to come up from time to time, adding to some of the knee-jerk market swings.
M&A: Getting Bigger and Replenishing Pipelines
There were several major deals blocked by regulators in early 2017 on antitrust grounds. Insurers Aetna (AET) and Humana’s (HUM) merger got a no after a few years of trying, and Anthem (ANTM) and Cigna (CI) also got a no. Now, there are more deals in the works.
CVS Health (CVS) announced in December it had agreed to acquire AET for $69 billion. That deal is still under regulatory review and has yet to be approved. CI announced at the beginning of March that it had entered a definitive agreement to acquire pharmacy benefits manager Express Scripts (ESRX) for $52 billion. CI said it expects the deal to close before Dec. 31, 2018, pending regulatory approval.
While insurers and other healthcare companies have been looking to integrate, the drugmakers have been looking to replenish their pipelines. There’s been a couple of deals on the larger side in biotech since the start of 2018. On Monday, Jan. 22, French drugmaker Sanofi announced it would buy Biogen-spinout Bioverativ (BIVV) for $11.6 billion. The same day, Celgene (CELG) announced it would acquire Juno Therapeutics (JUNO) for $9 billion. Both of those deals closed in early March.
Some analysts interpreted the biotech deals as a sign there would be more M&A in 2018, spurred by tax reform and access to overseas earnings. At the same time, however, other analysts note that lofty valuations in the space might hold back further deals.
For market commentary throughout earnings season and all year round, keep an eye on the Ticker Tape for Chief Market Strategist JJ Kinahan’s daily Market Update and earnings previews ahead of major reports.
Looking for an advanced trading platform with tools to help you stay on top of the markets during earnings season? Check out the thinkorswim® platform from TD Ameritrade.